Thyroid hormone and its metabolites in relation to quality of life in patients treated for differentiated thyroid cancer

Abstract

We did not find any association between TFTs and QoL in athyreotic patients on LT4 monotherapy. Our data do not provide evidence that a slight increase in dose improves fatigue or well-being in hypothyroid patients on LT4 therapy.